Orphazyme ApS Snags $19.7M In Series A for Hsp70 Program
By Marie Powers
Thursday, September 8, 2011
Danish biopharmaceutical company Orphazyme ApS raised €14 million (US$19.7 million) in a Series A financing to move its lead program, Orph-001, into the clinic. The company, based in Copenhagen, is pursuing technology related to molecular chaperone heat-shock protein 70 (Hsp70) to treat disorders known as lysosomal storage diseases (LSD) a family of more than 45 often-fatal genetic disorders with few existing treatment options.
Outside of the US
Part of Thomson Reuters
Note: our contact information has changed
In the U.S. and Canada: +1-800-336-4474
Outside the U.S.: +44-203-684-1796
Hours: Monday - Friday, 8:00am - 6:00 pm EST
© 2017 Thomson Reuters. Reproduction, reposting content is strictly prohibited.